Autoantibody, Renal Carcinoma, Serology
Conditions
Keywords
Renal Carcinoma, Autoantibody, serology
Brief summary
This project aims to construct a multicenter retrospective study by retrospectively collecting clinical, serological, and pathological data from patients. A comprehensive data management system will be established to facilitate the integration and analysis of multicenter data, alongside antibody profiling characteristics. A predictive model based on serological autoantibody profiles will be developed and validated using both internal and external cohorts. This model will predict clinical prognostic factors in renal carcinoma and identify patient populations likely to respond to immunotherapy. By enabling personalized treatment decisions and minimizing unnecessary treatment risks, the model aims to improve patient quality of life and overall prognosis.
Interventions
None listed
Sponsors
China-Japan Friendship Hospital
The First Affiliated Hospital of Xiamen University
First Affiliated Hospital of Fujian Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Pathological diagnosis of ccRCC; * Availability of complete clinical, pathological, and follow-up data; * Sufficient preoperative serum available for collection; * Well-preserved pathological slides for subsequent immunohistochemical (chip) analysis; * At least one post-treatment follow-up/efficacy evaluation.
Exclusion criteria
* Therapeutic contraindication cohort: Individuals presenting with severe comorbidities rendering them medically ineligible for therapeutic interventions; * Oncological multiplicity: Subjects with either (a) antecedent therapeutic regimens targeting non-index malignancies or (b) concurrent diagnosis of untreated active malignancies; * Biospecimen integrity violation: Cases demonstrating serum hemolysis or compromised specimen integrity; * Data insufficiency cohort: Patients exhibiting incomplete clinical/pathological records or insufficient longitudinal follow-up data for comprehensive analysis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| serum autoantibodies | Prior to any treatment or surgery, 5 mL of venous blood was collected from each individual and allowed to stand at room temperature (RT) for 1 hour to facilitate coagulation. | After incubating the serum on the HuProt array, autoantibody signals were detected, standardized, and quantified. For the selection of candidate proteins, three criteria must be met when comparing ccRCC with healthy controls: (1) a p-value ≤ 0.05 obtained from the t-test; (2) a fold change (FC) ≥ 1.2; (3) a positivity rate ≥ 10% (ccRCC positive reactivity is defined as values greater than the average of the healthy control group plus 2× SD. The positivity rate is calculated as the ratio of ccRCC positive responses to the total number of responses). |
Countries
China
Outcome results
None listed